Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24


Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer.

Hosford SR, Shee K, Wells JD, Traphagen NA, Fields JL, Hampsch RA, Kettenbach AN, Demidenko E, Miller TW.

Mol Oncol. 2019 Jun 10. doi: 10.1002/1878-0261.12528. [Epub ahead of print]


Calcifications mimicking ductal carcinoma in situ in a patient with end-stage renal disease.

Shee K, Veilleux LW, Linos K, Marotti JD.

Breast J. 2019 Jun 6. doi: 10.1111/tbj.13392. [Epub ahead of print] No abstract available.


Diarylidenylpiperidones, H-4073 and HO-3867, Induce G2/M Cell-Cycle Arrest, Apoptosis and Inhibit STAT3 Phosphorylation in Human Pancreatic Cancer Cells.

Mast JM, Tse D, Shee K, Lakshmi Kuppusamy M, Kmiec MM, Kálai T, Kuppusamy P.

Cell Biochem Biophys. 2019 Jun;77(2):109-119. doi: 10.1007/s12013-019-00873-6. Epub 2019 May 14.


Biomarkers to diagnose metastatic breast carcinoma to the pancreas: A case report and update.

Shee K, Strait AM, Liu X.

Diagn Cytopathol. 2019 May 14. doi: 10.1002/dc.24210. [Epub ahead of print]


A novel ex vivo trainer for robotic vesicourethral anastomosis.

Shee K, Koo K, Wu X, Ghali FM, Halter RJ, Hyams ES.

J Robot Surg. 2019 Jan 28. doi: 10.1007/s11701-019-00926-1. [Epub ahead of print]


Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing.

Shee K, Muller KE, Marotti J, Miller TW, Wells WA, Tsongalis GJ.

Am J Pathol. 2019 May;189(5):956-965. doi: 10.1016/j.ajpath.2018.08.020. Epub 2018 Oct 29. Review.


Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer.

Shee K, Jiang A, Varn FS, Liu S, Traphagen NA, Owens P, Ma CX, Hoog J, Cheng C, Golub TR, Straussman R, Miller TW.

FASEB J. 2019 Feb;33(2):1644-1657. doi: 10.1096/fj.201801241R. Epub 2018 Aug 30.


Following the crowd: patterns of crowdsourcing on Twitter among urologists.

Koo K, Shee K, Gormley EA.

World J Urol. 2019 Mar;37(3):567-572. doi: 10.1007/s00345-018-2405-5. Epub 2018 Jul 16.


Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.

Shee K, Yang W, Hinds JW, Hampsch RA, Varn FS, Traphagen NA, Patel K, Cheng C, Jenkins NP, Kettenbach AN, Demidenko E, Owens P, Faber AC, Golub TR, Straussman R, Miller TW.

J Exp Med. 2018 Mar 5;215(3):895-910. doi: 10.1084/jem.20171818. Epub 2018 Feb 7.


The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53.

Madan E, Parker TM, Bauer MR, Dhiman A, Pelham CJ, Nagane M, Kuppusamy ML, Holmes M, Holmes TR, Shaik K, Shee K, Kiparoidze S, Smith SD, Park YA, Gomm JJ, Jones LJ, Tomás AR, Cunha AC, Selvendiran K, Hansen LA, Fersht AR, Hideg K, Gogna R, Kuppusamy P.

J Biol Chem. 2018 Mar 23;293(12):4262-4276. doi: 10.1074/jbc.RA117.000950. Epub 2018 Jan 30.


Trailblazing Precision Oncology for Rare Tumor Subtypes.

Shee K, Miller TW.

Oncologist. 2018 Feb;23(2):143-144. doi: 10.1634/theoncologist.2017-0494. Epub 2017 Nov 20. No abstract available.


Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer.

Yang W, Hosford SR, Traphagen NA, Shee K, Demidenko E, Liu S, Miller TW.

FASEB J. 2018 Mar;32(3):1222-1235. doi: 10.1096/fj.201700477R. Epub 2018 Jan 3.


Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.

Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M, Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA, Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR, Straussman R.

Science. 2017 Sep 15;357(6356):1156-1160. doi: 10.1126/science.aah5043.


Pain Management in Penile Prosthetic Surgery: A Review of the Literature.

Reinstatler L, Shee K, Gross MS.

Sex Med Rev. 2018 Jan;6(1):162-169. doi: 10.1016/j.sxmr.2017.05.005. Epub 2017 Jul 21. Review.


Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.

Hampsch RA, Shee K, Bates D, Lewis LD, Désiré L, Leblond B, Demidenko E, Stefan K, Huang YH, Miller TW.

Oncotarget. 2017 Mar 28;8(13):21806-21817. doi: 10.18632/oncotarget.15586.


Maximizing the Benefit-Cost Ratio of Anthracyclines in Metastatic Breast Cancer: Case Report of a Patient with a Complete Response to High-Dose Doxorubicin.

Shee K, Kono AT, D'Anna SP, Seltzer MA, Lu X, Miller TW, Chamberlin MD.

Case Rep Oncol. 2016 Dec 8;9(3):840-846. doi: 10.1159/000453608. eCollection 2016 Sep-Dec. Erratum in: Case Rep Oncol. 2017 Feb 2;10 (1):152.


Practice Makes Perfect: Correlations Between Prior Experience in High-level Athletics and Robotic Surgical Performance Do Not Persist After Task Repetition.

Shee K, Ghali FM, Hyams ES.

J Surg Educ. 2017 Jul - Aug;74(4):630-637. doi: 10.1016/j.jsurg.2016.12.008. Epub 2017 Jan 10.


Readability analysis of online health information about overactive bladder.

Koo K, Shee K, Yap RL.

Neurourol Urodyn. 2017 Sep;36(7):1782-1787. doi: 10.1002/nau.23176. Epub 2016 Oct 29.


Alpha-synuclein (SNCA) polymorphisms exert protective effects on memory after mild traumatic brain injury.

Shee K, Lucas A, Flashman LA, Nho K, Tsongalis GJ, McDonald BC, Saykin AJ, McAllister TW, Rhodes CH.

Neurosci Lett. 2016 Sep 6;630:241-246. doi: 10.1016/j.neulet.2016.07.057. Epub 2016 Jul 29.


Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.

Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates D, Lewis LD, Marotti JD, Eastman AR, Miller TW.

Clin Cancer Res. 2016 May 1;22(9):2250-60. doi: 10.1158/1078-0432.CCR-15-2276. Epub 2016 Jan 5.


Cell Competition During Growth and Regeneration.

Gogna R, Shee K, Moreno E.

Annu Rev Genet. 2015;49:697-718. doi: 10.1146/annurev-genet-112414-055214. Review.


The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.

Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW.

Breast Cancer Res Treat. 2015 Jan;149(1):69-79. doi: 10.1007/s10549-014-3201-6. Epub 2014 Dec 10.


Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR.

Nature. 2012 Jul 26;487(7408):500-4. doi: 10.1038/nature11183.


Research, collaboration, and open science using web 2.0.

Shee K, Strong M, Guido NJ, Lue RA, Church GM, Viel A.

J Microbiol Biol Educ. 2010 Dec 20;11(2):130-4. doi: 10.1128/jmbe.v11i2.219. Print 2010.

Supplemental Content

Loading ...
Support Center